In 1982, the French–American–British (FAB) cooperative group proposed a classification of
myelodysplastic syndromes (MDS) based on morphological features in blood and bone …

… to validate it in a large cohort of patients with MDS or transformed AML from the EBMT
database. Although the IPSS-R was originally developed for untreated MDS … with MDS and MDS …

… We conducted a single-center retrospective validation cohort study including adults with a
known diagnosis of MDS referred to OHSU from 2019 through 2021. The study was approved …

… Myelodysplastic syndromes (MDS) are heterogeneous neoplasms ranging from indolent …
Our study may present some limitations, mainly because of the retrospective nature of the …

… the prognostic power of the NPCRC in patients who have myelodysplastic syndrome (MDS). …
was small, this is first report to validate the NPCRC in MDS among the Korean population. …

… -center retrospective validation cohort study of adults with a known diagnosis of MDS referred
… Patients were identified using relevant diagnostic codes for MDS and those who were <18 …

… The primary limitation of our study is its retrospective nature. In particular, the number of visits
… Also, we did not validate DT findings against other measures, such as the Hospital Anxiety …

… in patients with myelodysplastic syndromes (MDS). To this … of 311 patients with primary MDS
diagnosed between October 1990 … Besides, the four scoring systems discriminated our MDS …

… These incidence data have been validated by the Dusseldorf MDS registry (and others),
which conducted central pathological review of bone marrow samples, and have finally …

… This study aimed to validate the findings of the original in a large cohort of MDS patients,
as well as assess its validity in therapy-related and hypoplastic MDS. We retrospectively …